Organization (Industry)
Menarini Group (Italy)
ClinicalTrials.gov lists Menarini Group (Italy) as lead sponsor of 50 trials, counting the companies grouped under it. Menarini Group (Italy) itself has 9 active development programs and 14 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 2 registered with a 2026 start date. The dashed outline is the pace from the 2 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo A.Menarini Industrie Farmaceutiche Riunite S.r.l., via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers Menarini Group (Italy) and 1 company grouped under it: 50 lead-sponsored trials (28 its own, 22 in the grouped companies) and 4 legal-entity registrations (3 its own, 1 in the grouped companies).
Companies grouped under this page (1)
| Company | Lead trials | Legal entities |
|---|---|---|
| Stemline Therapeutics (United States) | 22 | 1 |
Disease areas (55)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Breast Neoplasms | 16 |
| Leukemia, Myeloid, Acute | 10 |
| Lymphoma | 8 |
| Hematologic Neoplasms | 7 |
| Pain | 6 |
Showing 5 of 55 disease areas.
Trials by start year as sponsor or collaborator (22)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 3 |
| 2024 | 1 |
| 2023 | 4 |
| 2022 | 1 |
| 2020 | 1 |
| 2019 | 2 |
| 2018 | 1 |
| 2017 | 4 |
| 2016 | 2 |
Showing 10 of 22 years.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (9)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Nepadutant | Colic | Phase 2 | 2 |
| MEN1611 | Colorectal Neoplasms | Phase 1/2 | 1 |
| MEN1703 | Leukemia, Myeloid, Acute | Phase 1/2 | 1 |
| CETUXIMAB | Colorectal Neoplasms | Phase 1/2 | 1 |
| MEN1611 | Breast Neoplasms | Phase 1 | 1 |
Showing 5 of 9 active programs.
Approved assets (14)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Tramadol Hydrochloride/Dexketoprofen Trometamol | 1 |
| Tramadol HCl-Paracetamol | 1 |
| Febuxostat | 2 |
| Delafloxacin | 1 |
| Allopurinol | 1 |
Showing 5 of 14 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 38% hit target (n=8) | 38% on time (n=8) |
Journals published in (104)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Annals of oncology : official journal of the European Society for Medical Oncology | 10 |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 9 |
| The New England journal of medicine | 9 |
| Clinical cancer research : an official journal of the American Association for Cancer Research | 8 |
| Blood | 7 |
Showing 5 of 104 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 10 | 4 | 2025-07-15 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 3 | 2025-09-29 |
Organization relationships (16)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Medical University of Graz | Co sponsors trial with | 2 |
| PRA Health Sciences | Uses vendor | 1 |
| UCLA Health | Co sponsors trial with | 1 |
| Iomedico (Germany) | Co sponsors trial with | 1 |
| Medpace Holdings, Inc. | Uses vendor | 1 |
Showing 5 of 16 relationships.
Latest dated events (100)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-12-18 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-09-13 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08-18 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-03-25 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-02-02 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 100 events.
Biomarker capability evidence (134)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ATP12A | Trial sponsor | Named in trial inclusion criteria |
| ATP4A | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 134 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.